A Study of Darvadstrocel for Treating Complex Perianal Fistulas in Children and Teenagers With Crohn's Disease

February 19, 2024 updated by: Takeda

A Phase 3, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Darvadstrocel in the Treatment of Complex Perianal Fistula in Pediatric Subjects With Crohn's Disease Over a Period of 24 Weeks and an Extended Follow-up Period for a Total of up to 52 Weeks

A perianal fistula is an abnormal passageway that develops between the rectum and the skin near the anus. The fistula is considered complex if it branches into several openings or an abscess is also present.

The main aim of this study is to learn if complex perianal fistulas in children and teenagers close after treatment with darvadstrocel.

2 to 3 weeks before treatment with darvadstrocel, each participant will have surgery to clean the fistula and to drain any abscesses. On the day of treatment, each participant will have the fistula cleaned and will receive an injection of darvadstrocel near the fistula, under anesthetic.

For up to 1 year after treatment, participants will regularly visit the clinic for follow-up. The fistula will be examined and any side effects from the treatment will be recorded. Participants will have an MRI at one clinic visit (about 24 weeks after treatment).

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

The drug being tested in this study is called darvadstrocel (Cx601, cell suspension containing 120 million cells of allogeneic expanded adipose-derived mesenchymal stem cells [eASCs]). Darvadstrocel is being tested to treat complex perianal fistula in pediatric participants who have Crohn's disease (CD). This study will look at the safety and efficacy of darvadstrocel in the treatment of complex perianal fistula in CD.

The study will enroll at least 20 patients who will receive a single dose of darvadstrocel.

This multi-center trial will be conducted worldwide. The overall time to participate in this study is 52 weeks.

Participants will make multiple visits to the clinic. In unavoidable circumstances, such as the coronavirus disease 2019 pandemic, exceptions may be granted for alternative methods for conducting participant visits with approval by the medical monitor and/or sponsor.

Study Type

Interventional

Enrollment (Estimated)

20

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Takeda Study Registration Call Center
  • Phone Number: +1-877-825-3327
  • Email: medinfoUS@takeda.com

Study Locations

  • Israel
      • Be'er Ya'aqov, Israel, 7033001
        • Recruiting
        • Shamir Medical Center (Assaf Harofeh)
        • Contact:
        • Principal Investigator:
          • EFRAT BROIDE
      • Haifa, Israel, 3109601
        • Recruiting
        • Rambam Health Care Campus
        • Principal Investigator:
          • Ron Shaoul
        • Contact:
      • Jerusalem, Israel, 91031
        • Recruiting
        • Shaare Zedek Medical Center
        • Principal Investigator:
          • Dan Turner
        • Contact:
      • Jerusalem, Israel, 9124001
        • Recruiting
        • Hadassah University Hospital-Mt. Scopus
        • Principal Investigator:
          • Zev Davidovics
        • Contact:
      • Petach-Tikva, Israel, 4920235
        • Recruiting
        • Schneider Children's Medical Center
        • Principal Investigator:
          • Raanan Shamir
        • Contact:
  • Japan
      • Bunkyo-ku, Japan, 113-8431
        • Recruiting
        • Juntendo University Hospital
        • Principal Investigator:
          • Takahiro Kudo
        • Contact:
      • Bunkyo-ku, Japan, 113-8519
        • Recruiting
        • Medical Hospital, Tokyo Medical and Dental University
        • Principal Investigator:
          • Masakazu Nagahori
        • Contact:
      • Sendai-shi, Japan, 989-3126
        • Recruiting
        • Miyagi Children's Hospital
        • Contact:
        • Principal Investigator:
          • Daiki Abukawa
      • Shimotsuke-shi, Japan, 329-0498
        • Recruiting
        • Jichi Medical University Hospital
        • Contact:
        • Principal Investigator:
          • Hideki Kumagai
      • Tsu-shi, Japan, 514-8507
        • Recruiting
        • Mie University Hospital
        • Contact:
        • Principal Investigator:
          • Keiichi Uchida
  • Netherlands
      • Amsterdam, Netherlands, 1105 AZ
        • Recruiting
        • Amsterdam UMC, Locatie AMC
        • Contact:
        • Principal Investigator:
          • Johan Van Limbergen
      • Groningen, Netherlands, 9713 GZ
        • Recruiting
        • Universitair Medisch Centrum Groningen (Umcg)
        • Contact:
        • Principal Investigator:
          • Patrick van Rheenen
      • Rotterdam, Netherlands, 3000 CA
        • Recruiting
        • Erasmus Medisch Centrum
        • Contact:
        • Principal Investigator:
          • Lissy De Ridder
  • Poland
      • Krakow, Poland, 30-663
        • Recruiting
        • Uniwersytecki Szpital Dzieciecy w Krakowie
        • Contact:
        • Principal Investigator:
          • Malgorzata Sladek
      • Rzeszow, Poland, 35-302
        • Recruiting
        • Gabinet Lekarski Bartosz Korczowski
        • Principal Investigator:
          • Bartosz Korczowski
        • Contact:
      • Warszawa, Poland, 04-730
        • Recruiting
        • Instytut "Pomnik - Centrum Zdrowia Dziecka"
        • Principal Investigator:
          • Jaroslaw Kierkus
        • Contact:
  • Spain
      • Badalona, Spain, 8916
        • Recruiting
        • Hospital Universitari Germans Trias I Pujol
        • Contact:
        • Principal Investigator:
          • Maria Oviedo Gutierrez
      • Barcelona, Spain, 8035
        • Recruiting
        • Hospital Universitari Vall d'Hebron
        • Contact:
        • Principal Investigator:
          • Oscar Segarra Canton
      • Barcelona, Spain, 8950
        • Recruiting
        • Hospital Sant Joan de Deu
        • Contact:
        • Principal Investigator:
          • Francisco Javier Martin Carpi
      • Madrid, Spain, 28009
        • Recruiting
        • Hospital Infantil Universitario Nino Jesus
        • Contact:
        • Principal Investigator:
          • Jose Lorenzo Alonso Calderon
      • Madrid, Spain, 28040
        • Recruiting
        • Hospital Universitario Fundacion Jimenez Diaz
        • Contact:
        • Principal Investigator:
          • Maria de los Angeles Martinez Ibeas
      • Malaga, Spain, 29011

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

2 years to 15 years (Child)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  1. Has a CD diagnosis based on accepted clinical, endoscopic, histological and/or radiologic criteria at least 6 months before the screening visit.
  2. Has complex perianal fistula refractory to at least one of the following treatments: immunosuppressants or biologics (anti-TNFs, anti-integrin, anti-interleukin [IL] 12/23). Fistula(s) refractory to therapy is defined in this study as follows: Immunosuppressants: Inadequate response after 3 months, based on clinical assessment, or more treatment with azathioprine, 6-mercaptopurine or methotrexate. Biologics: Inadequate response after 14 weeks (16 weeks for anti-IL 12/23), based on clinical assessment, or more standard treatment for induction and maintenance.

  3. A complex perianal fistula(s) that meets one or more of the following criteria, modified from the American Gastroenterological Association (AGA) technical review: High intersphincteric, transsphincteric, extrasphincteric, or suprasphincteric as assessed by MRI. Presence of 2 or 3 external openings (tracts) as assessed by clinical examination. Associated fluid (abscess) collections as determined by MRI.

    This study requires that the participant has complex perianal fistulas with a maximum of 2 internal openings and a maximum of 3 external openings, based on clinical assessment. Darvadstrocel treatment is targeted for fistulas that connect between internal and external openings. A central reading of a locally performed pelvic MRI will be performed to confirm the location of the fistula and potential associated perianal abscess(es). Fistulas must have been draining for at least 6 weeks before the screening visit. Participants with actively draining simple subcutaneous fistulas, at the time of the screening visit, are not allowed in this study.

  4. Has inactive or mildly active luminal CD defined by meeting all of the following criteria:

    1. Colonoscopy, flexible sigmoidoscopy or rectoscopy performed either at screening or within the 6 months before screening, demonstrating no rectal ulcers larger than 0.5 cm. A participant who has documented rectal ulcers larger than 0.5 cm within the 6 months before screening but has undergone subsequent treatment may be eligible if there are no rectal ulcers larger than 0.5 cm on a sigmoidoscopy or rectoscopy performed after treatment or at the time of screening.
    2. The improvement of, or no worsening in stool frequency, sustained for 1 week or more, in the interval between the colonoscopy, flexible sigmoidoscopy or rectoscopy in inclusion criteria 4(a) and the screening visit.
    3. No initiation or intensification of treatment with corticosteroids, immunosuppressants, or monoclonal antibody dose regimen between the colonoscopy, flexible sigmoidoscopy or rectoscopy in inclusion criteria 4(a) and the screening visit.

Exclusion Criteria:

  1. Has received any investigational compound within 12 weeks/84 days before screening.
  2. Has received darvadstrocel/eASC in a previous clinical study or as a therapeutic agent.
  3. The participant weighs <10 kg at screening.
  4. Has concomitant perianal fistula(s) with only internal or external opening(s).
  5. Has concomitant internal fistula(s) such as ileo-vesical, rectovaginal or ileo-colonic fistula(s).
  6. Has an abscess >2 cm, unless resolved in the preparation procedure.
  7. Has rectal and/or anal stenosis, and/or active proctitis, which would restrict the surgical procedure.
  8. The participant underwent surgery for the fistula other than drainage or seton placement.
  9. Has diverting stomas.
  10. Has ongoing systemic corticosteroid treatment or has been treated with systemic corticosteroids within 4 weeks before screening.
  11. The participant requires new treatment with immunosuppressants/anti-TNF agents during the screening period.
  12. The participant has known or suspected COVID-19 by the investigator within the past 2 months (additional testing may be performed at the discretion of the investigator). Positive antibody testing for COVID without other evidence of current or recent active infection does not exclude participation. Participants who were in screening at the time that COVID-19-related factors resulted in discontinuation may also be rescreened with approval of the sponsor or designee.
  13. The participant requires surgery in the perianal region for reasons other than fistulas at the time of screening or foreseen either during the study and/or during the 24 weeks after treatment administration.
  14. Has malignant tumor or a prior history of any malignant tumor, including any type of fistula carcinoma.
  15. Has current or recent (within 3 months before the screening) history of abnormal, severe, progressive, uncontrolled hepatic, hematologic, gastrointestinal (except CD), endocrine, pulmonary, cardiac, neurological, psychiatric, or cerebral disease.
  16. Has either congenital or acquired immunodeficiencies, including participants known to be HIV carriers or participants with, in the judgment of the investigator, are suspected to have monogenic inflammatory bowel disease.
  17. Has previously received a bone marrow transplant.
  18. Has a contraindication to MRI scan or other planned study procedures.
  19. Has a contraindication to the anesthetic procedure.
  20. Had major surgery or severe trauma within 6 months before the screening visit.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Darvadstrocel
Darvadstrocel (Cx601), 24 mL suspension of 120 million cells as a perilesional injection, once on Day 0.
Biological: Darvadstrocel
Darvadstrocel perilesional injection.
Other Names:
  • Cx601

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Percentage of Participants who Achieve Combined Remission
Time Frame: Week 24
Combined remission is defined as the closure of all treated external openings that were draining at baseline despite gentle finger compression, and absence of abscess(es) >2 cm (in at least 2 dimensions) of the treated perianal fistula(s) confirmed by central magnetic resonance imaging (MRI) assessment.
Week 24

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Percentage of Participants who Achieve Clinical Remission
Time Frame: Up to Week 52
Clinical remission is defined as the closure of all treated external openings that were draining at baseline despite gentle finger compression.
Up to Week 52
Percentage of Participants who Achieve Clinical Response
Time Frame: Up to Week 52
Clinical response is defined as closure of at least 50% of all treated external openings that were draining at baseline despite gentle finger compression.
Up to Week 52
Time to Clinical Remission
Time Frame: Up to Week 52
Time to Clinical Remission is defined as the time in weeks from treatment start to first visit at which clinical remission is observed before Week 52; where clinical remission is said to occur if a clinical assessment shows closure of all treated external openings that were draining at baseline despite gentle finger compression.
Up to Week 52
Time to Clinical Response
Time Frame: Up to Week 52
Time to clinical response defined as the time in weeks from treatment start to first visit at which clinical response is observed before Week 52; where clinical response is said to occur if a clinical assessment shows closure of at least 50% of all treated external openings that were draining at baseline despite gentle finger compression.
Up to Week 52
Percentage of Participants with Relapse in Participants with Combined Remission at Week 24
Time Frame: Up to Week 52
Relapse is defined as reopening of any of the treated fistula(s) external openings with active drainage as clinically assessed in participants who were in combined remission at Week 24.
Up to Week 52
Percentage of Participants with At Least One Adverse Event (AE)
Time Frame: Up to Week 52
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment.
Up to Week 52
Percentage of Participants with At Least One Serious Adverse Event (SAE)
Time Frame: Up to Week 52
An SAE is defined as an untoward medical occurrence, significant hazard, contraindication, side effect or precaution that at any dose: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant.
Up to Week 52
Percentage of Participants with At Least One Adverse Event of Special Interest (AESI)
Time Frame: Up to Week 52
An AESI include immunogenicity/alloimmune reactions, hypersensitivity, ectopic tissue formation, medication errors, tumorigenicity, transmission of infectious agents.
Up to Week 52
Percentage of Participants with Potentially Clinically Significant Vital Sign Values
Time Frame: Up to Week 52
Vital signs will include body temperature (oral measurement), blood pressure (systolic and diastolic, resting more than 5 minutes), and heart rate (beats per minute).
Up to Week 52
Percentage of Participants with Potentially Clinically Significant Laboratory Values
Time Frame: Up to Week 52
Laboratory parameters will include hematology, biochemistry, and urinalysis.
Up to Week 52

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Takeda

Collaborators

Takeda Development Center Americas, Inc.

Investigators

  • Study Director: Medical Director, Takeda

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 30, 2021

Primary Completion (Estimated)

June 30, 2025

Study Completion (Estimated)

December 31, 2025

Study Registration Dates

First Submitted

January 6, 2021

First Submitted That Met QC Criteria

January 7, 2021

First Posted (Actual)

January 8, 2021

Study Record Updates

Last Update Posted (Actual)

February 20, 2024

Last Update Submitted That Met QC Criteria

February 19, 2024

Last Verified

February 1, 2024

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Darvadstrocel-3004
  • 2020-003193-48 (EudraCT Number)
  • EMEA-001561-PIP01-13-M02 (Other Identifier: EU PIP number)
  • 2023-503973-39 (Other Identifier: EU CTIS Number)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

IPD Sharing Access Criteria

IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • ICF
  • CSR

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Crohn's Disease

Clinical Trials on Darvadstrocel

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Burundi

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe